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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORLimited Usefulness of the
Modiﬁed Academic Research
Consortium Stent Thrombosis
Deﬁnition for Clinical Trials
Validation of the Academic Research Consortium stent thrombo-
sis (ST) definitions (1) is most valuable, particularly for the group
of cases with “possible” ST (i.e., any unexplained death beyond 30
days), which are most controversial and therefore excluded from
many trial reports. Unfortunately, the presented analysis (1), based
on autopsy data and to a limited 1-year follow-up, has limitations
in its application to clinical trial data. In an attempt to shed more
light onto the relation between unexplained death and ST during
a prolonged follow-up from a clinical point of view, we scrutinized
the circumstances of all unexplained deaths defined as possible ST
by an independent Critical Events Committee occurring up to 3
years after stenting in the “real-world” BASKET (Basel Stent
Cost-Effectiveness) trial (n  17) (2). ST was labeled—on the
asis of a detailed review of all patient files, autopsy reports,
ngiographic films, as well as interviews with the relatives and
amily doctors of patients—“likely” if an acute myocardial infarc-
ion was clinically suspected or the patient had preserved left
entricular (LV) function, whereas it was deemed “unlikely” in
ases with severe comorbidities, markedly reduced LV function, or
uspected pulmonary embolism (3). Possible ST was “likely” in 10
f 17 cases (59%: suspected infarction, n  4; preserved LV
unction, n  6) and “unlikely” in 7 of 17 (41%: suspected
ulmonary embolism, n  3, severe comorbidities, n  4). These
linical results are in accordance with the autopsy-based findings
y Cutlip et al. (1) and extend them to the clinical trial arena.
ogether, they underscore the importance of a very detailed
nalysis of the clinical circumstances of death, particularly late
nexpected death, in order not to miss or underreport very late
T. Here the proposed “modified possible ST” definition might
rove helpful, particularly if extended to clinical circumstances
f late ST.
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Reply
We thank Dr. Pfisterer and colleagues for their interest in our
study and for sharing their data from the BASKET (Basel Stent
Cost-Effectiveness) trial. We agree our results are limited by
relatively short-term follow-up after stenting (25% of patients
followed beyond 1 year) and a population defined by autopsy. On
the basis of our objective to assess validity of clinical adjudication
according to the sensitivity and specificity of Academic Research
Consortium (ARC) criteria, the autopsy data were the necessary
gold standard.
The data provided by these investigators on the basis of detailed
clinical assessment from a real-world clinical trial are also helpful.
Given that autopsy data will not be available in all cases of
suspected stent thrombosis within a clinical trial, we agree with the
importance of detailed assessment of clinical data to minimize
uncertainty in the cause of death as stated in our paper (1). As they
suggest, such a clinical assessment that is based on the criteria
proposed for modification of the ARC possible criteria could be
useful to determine which late deaths are more likely to be
associated with late or very late stent thrombosis.
Thus, we concur that the most accurate assessment of stent
thrombosis within a clinical trial requires detailed and complete
collection of data regarding the cause of death. Whenever possible,
we would encourage that this include autopsy specimens of the
stented segment, especially in clinical trials for which stent
thrombosis is a primary endpoint of interest. We are encouraged
that the clinical trial data are consistent with our findings from
pathological data. Although both pathological and clinical data
suggest that modification of the ARC possible criteria might
improve the estimate of the true event rate, specifically related to
the underreporting of events with only the more sensitive but less
specific definite or probable criteria, more evidence will be needed
to assess whether such a modification improves discernment of
safety differences between coronary stents or pharmacological
therapies designed to reduce stent thrombosis. Finally, it is
important to recognize that all clinical definitions of a pathological
event will necessarily be limited. Despite these imperfections,
consistency inherent with the use of consensus definitions remains
the key objective and enormously more informative across the
published data involving the reporting of infrequent events,
wherein comparability between clinical trials or “poolability” of
clinical trial data might be required for optimal assessment.
